001     189847
005     20210129215450.0
024 7 _ |a 10.1038/jid.2015.184
|2 doi
024 7 _ |a WOS:000360995600016
|2 WOS
024 7 _ |a altmetric:4184180
|2 altmetric
024 7 _ |a pmid:25961909
|2 pmid
037 _ _ |a FZJ-2015-02853
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Homberg, Melanie
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Distinct impact of two keratin mutations causing epidermolysis bullosa simplex on keratinocyte adhesion and stiffness
260 _ _ |a Basingstoke [u.a.]
|c 2015
|b Nature Publishing Group
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1441970575_19445
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a Keratin filaments constitute the major component of the epidermal cytoskeleton from heterodimers of type I and type II keratin subunits. Missense mutations in keratin 5 or keratin 14, highly expressed in the basal epidermis, cause the severe skin blistering disease epidermolysis bullosa simplex (EBS) in humans by rendering the keratin cytoskeleton sensitive to mechanical stress; yet, the mechanisms by which individual mutations cause cell fragility are incompletely understood. Here, we compared the K14p.Arg125Pro with the K5p.Glu477Asp mutation, both giving rise to severe generalized EBS, by stable expression in keratin-free keratinocytes. This revealed distinctly different effects on keratin cytoskeletal organization, in agreement with in vivo observations, thus validating the cell system. Although the K14p.Arg125Pro mutation led to impaired desmosomes, downregulation of desmosomal proteins, and weakened epithelial sheet integrity upon shear stress, the K5p.Glu477Asp mutation did not impair these functions, although causing EBS with squamous cell carcinoma in vivo. Atomic force microscopy demonstrated that K14 mutant cells were even less resistant against deformation compared with keratin-free keratinocytes. Thus, a keratin mutation causing EBS compromises cell stiffness to a greater extent than the lack of keratins. Finally, re-expression of K14 in K14 mutant cells did not rescue the above defects. Collectively, our findings have implications for EBS therapy approaches.
536 _ _ |a 552 - Engineering Cell Function (POF3-552)
|0 G:(DE-HGF)POF3-552
|c POF3-552
|f POF III
|x 0
700 1 _ |a Ramms, Lena
|0 P:(DE-Juel1)151217
|b 1
|u fzj
700 1 _ |a Schwarz, Nicole
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Dreissen, Georg
|0 P:(DE-Juel1)129308
|b 3
|u fzj
700 1 _ |a Leube, Rudolf
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Merkel, Rudolf
|0 P:(DE-Juel1)128833
|b 5
|u fzj
700 1 _ |a Hoffmann, Bernd
|0 P:(DE-Juel1)128817
|b 6
|u fzj
700 1 _ |a Magin, Thomas M.
|0 P:(DE-HGF)0
|b 7
|e Corresponding Author
773 _ _ |a 10.1038/jid.2015.184
|0 PERI:(DE-600)2006902-9
|n 000
|p 2437–2445
|t The @journal of investigative dermatology
|v 135
|y 2015
|x 0022-202X
909 C O |o oai:juser.fz-juelich.de:189847
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)151217
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)129308
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)128833
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)128817
913 0 _ |a DE-HGF
|b Schlüsseltechnologien
|l BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung
|1 G:(DE-HGF)POF2-450
|0 G:(DE-HGF)POF2-453
|2 G:(DE-HGF)POF2-400
|v Physics of the Cell
|x 0
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-552
|2 G:(DE-HGF)POF3-500
|v Engineering Cell Function
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J INVEST DERMATOL : 2013
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J INVEST DERMATOL : 2013
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-7-20110106
|k ICS-7
|l Biomechanik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)ICS-7-20110106
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-2-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21